{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:06:30Z","timestamp":1790690790617,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000147","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021981","name":"Roche Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021981","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019211","name":"AbbVie Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019211","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000521","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000521","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bneo.2026.100233","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T16:11:27Z","timestamp":1776269487000},"page":"100233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A phase 1 study of R-GDP\u2013venetoclax before autologous transplant in relapsed\/refractory large B-cell lymphoma (CCTG LY.18)"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7638-1589","authenticated-orcid":false,"given":"Sarit","family":"Assouline","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Prica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4625-3009","authenticated-orcid":false,"given":"Diego","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0287-7124","authenticated-orcid":false,"given":"Robert","family":"Kridel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Kukreti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Shamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayan","family":"Kaedbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4727-1425","authenticated-orcid":false,"given":"Alina","family":"Gerrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5835-9863","authenticated-orcid":false,"given":"Kerry","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois E.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4581-3390","authenticated-orcid":false,"given":"Annette E.","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-5947","authenticated-orcid":false,"given":"David W.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Crump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6139-0696","authenticated-orcid":false,"given":"Bingshu E.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bneo.2026.100233_bib1","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2026.100233_bib2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.bneo.2026.100233_bib3","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1200\/JCO-25-00399","article-title":"Lisocabtagene maraleucel versus standard of care for second-line relapsed\/refractory large B-cell lymphoma: 3-year follow-up from the randomized, phase III TRANSFORM study","volume":"43","author":"Kamdar","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2026.100233_bib4","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100233_bib5","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1182\/blood-2024-206375","article-title":"A real-world comparison of CAR T-cell therapy versus a historical standard-of-care approach for relapsed-refractory large B-cell lymphoma in Ontario, Canada","volume":"144","author":"Kordbacheh","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2026.100233_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1397613","article-title":"Obstacles to global implementation of CAR T cell therapy in myeloma and lymphoma","volume":"14","author":"Medina-Olivares","year":"2024","journal-title":"Frontiers in Oncology"},{"issue":"27","key":"10.1016\/j.bneo.2026.100233_bib7","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.bneo.2026.100233_bib8","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bneo.2026.100233_bib9","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/bloodadvances.2020001646","article-title":"The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL","volume":"4","author":"Assouline","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.bneo.2026.100233_bib10","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/2159-8290.CD-17-0797","article-title":"Found in translation: how preclinical research is guiding the clinical development of the BCL2-selective inhibitor venetoclax","volume":"7","author":"Leverson","year":"2017","journal-title":"Cancer Discov"},{"issue":"27","key":"10.1016\/j.bneo.2026.100233_bib11","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2026.100233_bib12","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","article-title":"International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)","volume":"28","author":"Younes","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.bneo.2026.100233_bib13","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/bjh.19555","volume":"205","author":"Stewart","year":"2024","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.bneo.2026.100233_bib14","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2026.100233_bib15","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1111\/bjh.19764","article-title":"A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphoma","volume":"205","author":"Kuruvilla","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100233_bib16","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1186\/s12885-021-08225-5","article-title":"The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome","volume":"21","author":"Noring","year":"2021","journal-title":"BMC Cancer"},{"issue":"20","key":"10.1016\/j.bneo.2026.100233_bib17","first-page":"2493","article-title":"Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population","volume":"141","author":"Alduaij","year":"2023","journal-title":"Blood"},{"issue":"S2","key":"10.1016\/j.bneo.2026.100233_bib18","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/hon.3164_321","article-title":"Venetoclax combined with R-ICE (VICER) for second line treatment of diffuse large B cell lymphoma refractory or relapsed after initial chemoimmunotherapy","volume":"41","author":"Caimi","year":"2023","journal-title":"Hematological Oncology"},{"issue":"16","key":"10.1016\/j.bneo.2026.100233_bib19","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood-2017-08-802561","article-title":"A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL","volume":"131","author":"Sauter","year":"2018","journal-title":"Blood"},{"issue":"S3","key":"10.1016\/j.bneo.2026.100233_bib20","doi-asserted-by":"crossref","first-page":"70094","DOI":"10.1002\/hon.70094_322","article-title":"Epcoritamab + R-ICE in patients with relapsed\/refractory diffuse large B-cell lymphoma eligible for autologous stem cell transplantation: EPCORE NHL-2 [abstract]","volume":"43","author":"de Vos","year":"2025","journal-title":"Hematological Oncology"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100233_bib21","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1182\/blood-2024-198452","volume":"144","author":"Diefenbach","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100233_bib22","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1182\/blood-2022-158278","article-title":"Subcutaneous epcoritamab + R-Dhax\/C in patients with relapsed or refractory diffuse large B-cell lymphoma eligible for autologous stem cell transplant: updated phase 1\/2 results","volume":"140","author":"Abrisqueta","year":"2022","journal-title":"Blood"},{"issue":"S3","key":"10.1016\/j.bneo.2026.100233_bib23","doi-asserted-by":"crossref","first-page":"70096","DOI":"10.1002\/hon.70096_812","article-title":"Candian cancer trials group LY.18: a phase I master protocol of novel combination therapy for patients with relapsed\/refractory lymphoma\u2014the R-GDP-glofitamab substudy [abstract]","volume":"43","author":"Villa","year":"2025","journal-title":"Hematological Oncology"},{"issue":"suppl 16","key":"10.1016\/j.bneo.2026.100233_bib24","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.1200\/JCO.2024.42.16_suppl.7012","article-title":"Randomized phase II\/III study of R-CHOP +\/- venetoclax in previously untreated MYC\/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701","volume":"42","author":"Abramson","year":"2024","journal-title":"J Clin Oncology"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:18:35Z","timestamp":1790687915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2950328026000440"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100233","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 1 study of R-GDP\u2013venetoclax before autologous transplant in relapsed\/refractory large B-cell lymphoma (CCTG LY.18)","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100233","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100233"}}